Chang Lisa | TaiRx, Inc. | New Drug Development

TaiRx and Northwestern University Ann & Robert H. Lurie Children’s Hospital completed exclusive licensing deal for global development and market rights using Nodal protein as new biomarker to detect malignant tumor also for the treatment of various metastatic cancer.

2017/8/22 TaiRx Announces License Agreement with Northwestern University and Ann & Robert H. Lurie Children’s Hospital of Chicago, for Nodal Patents to Develop [...]

TaiRx and Northwestern University Ann & Robert H. Lurie Children’s Hospital completed exclusive licensing deal for global development and market rights using Nodal protein as new biomarker to detect malignant tumor also for the treatment of various metastatic cancer. Chang Lisa 2018-06-04T17:50:31+00:00

TaiRx held a pre-IPO institutional investors’ conference and announced the listing on Taiwan Emerging Market on the 20th of June.

2017/6/15 TaiRx shows its potential in new cancer drug development and will be listed on the emerging stock market on June 20th. […]

TaiRx held a pre-IPO institutional investors’ conference and announced the listing on Taiwan Emerging Market on the 20th of June. Chang Lisa 2018-06-04T17:50:50+00:00

TaiRx presents CVM-1118 Phase I Clinical Trial Progress at ASCO

2017/6/5 TaiRx, Inc. (6580) publishes its Phase I clinical trial result in the United States and Taiwan on CVM-1118, a new cancer drug, at [...]

TaiRx presents CVM-1118 Phase I Clinical Trial Progress at ASCO Chang Lisa 2018-06-04T17:50:56+00:00

Science reported TaiRx’s CVM-1118 as the first drug entering clinical trial, inhibiting the formation of vasculogenic mimicry in cancer.

2016/06/17 This issue of Science magazine (June 17, 2016) featured a column on how malignant tumor cells avoid traditional anti-angiogenesis mechanism and achieve metastasis. [...]

Science reported TaiRx’s CVM-1118 as the first drug entering clinical trial, inhibiting the formation of vasculogenic mimicry in cancer. Chang Lisa 2018-06-04T17:51:02+00:00

TaiRx’s oral cancer drug with a promising forecast.

2016/3/28 […]

TaiRx’s oral cancer drug with a promising forecast. Chang Lisa 2021-02-17T15:02:16+00:00

23 major pharmaceutical companies attended the cross-strait new drug discussion panel.

2016/3/18 […]

23 major pharmaceutical companies attended the cross-strait new drug discussion panel. Chang Lisa 2021-02-17T14:59:11+00:00

TaiRx receives Honorable recognition at the 12th Taiwan National Innovation Award.

2015/12/24 […]

TaiRx receives Honorable recognition at the 12th Taiwan National Innovation Award. Chang Lisa 2021-02-17T11:19:32+00:00

TaiRx received Honorable award at the 2015 Taiwan Healthcare and Agricultural Biotech Industries Innovation and Excellence Award Competition.

2015/9/24 […]

TaiRx received Honorable award at the 2015 Taiwan Healthcare and Agricultural Biotech Industries Innovation and Excellence Award Competition. Chang Lisa 2021-02-17T13:44:45+00:00

TaiRx received the Bronze Award at the 2015 Taipei Biotech Award Competition.

2015/7/24 Bio@Taipei […]

TaiRx received the Bronze Award at the 2015 Taipei Biotech Award Competition. Chang Lisa 2021-02-17T13:48:45+00:00

CVM-1118 IND approved by the US FDA to initiate Phase I clinical study in US.

2015/5/13 CVM-1118 from TaiRx, Inc. receives US FDA approval to initiate Phase I clinical study. TaiRx’s IND application received its approval in 30 days [...]

CVM-1118 IND approved by the US FDA to initiate Phase I clinical study in US. Chang Lisa 2018-06-04T17:51:46+00:00

About Chang Lisa